What is NETRIS Pharma?
NETRIS Pharma is a clinical-stage immuno-oncology company based in Lyon, France, operating within a comprehensive cancer center. The firm is dedicated to developing first-in-class therapeutics that target Netrin-1, a critical pathway for overcoming resistance in various oncology treatments. Leveraging a robust portfolio of intellectual property, NETRIS Pharma aims to deliver innovative solutions for patients who face challenges with existing chemotherapy, targeted therapy, and immunotherapy regimens. Strategic collaborations further bolster their research and clinical development capabilities, positioning the company as a key player in the biopharmaceutical landscape.
How much funding has NETRIS Pharma raised?
NETRIS Pharma has raised a total of $8.4M across 1 funding round:
Unspecified
$8.4M
Unspecified (2026): $8.4M with participation from Horizon Europe
Key Investors in NETRIS Pharma
Horizon Europe
Horizon Europe is a significant backer, likely providing crucial funding and strategic guidance to advance NETRIS Pharma's innovative immuno-oncology pipeline.
What's next for NETRIS Pharma?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal growth phase for NETRIS Pharma. This capital infusion is expected to accelerate the advancement of their Netrin-1 targeting therapeutics through clinical trials and towards potential market approval. The company's focus on overcoming treatment resistance in oncology positions it to address significant unmet medical needs, potentially leading to enhanced patient outcomes and a stronger market presence in the competitive biopharmaceutical sector.
See full NETRIS Pharma company page
